Healthcare

Australian drug development company Nyrada Inc. (ASX:NYR) has made significant progress in its clinical research, dosing its first group of patients in a Phase I trial for its lead drug candidate, NYR-BI03. The experimental treatment aims to reduce long-term disabilities associated with stroke and …

Australian healthcare services company Healius (ASX:HLS) has announced an ambitious EBIT margin target for FY27, aiming for a high single-digit percentage. This projection exceeds analyst expectations from both Citi and Jefferies, sparking mixed reactions from the market.

Despite an 8.1% decline in the ASX Healthcare Index, Jefferies remains optimistic about the medium-term growth prospects for Australia's healthcare services sector. The brokerage firm attributes this positive outlook to rising bulk billing rates and potential new government incentives, which could provide further financial …

Shares of Pro Medicus Limited (ASX:PME) took a sharp hit on Wednesday, tumbling nearly 8% after analysts revised their near-term earnings estimates. The latest dip means the ASX 200-listed health imaging technology company has now dropped 30% from its peak, raising questions about whether …

Shares of Healius (ASX:HLS) surged 11.8% on March 27, reaching A$1.465. This rise was driven by positive financial updates, including a 6.2% year-to-date revenue increase and a 4% jump in volumes for the company’s February results. If these gains hold, Healius is set to …

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, has announced the completion of clinical evaluations for the last patient in its ATH434-202 Phase 2 trial. This open-label study is designed to assess the safety, efficacy, …

Telix Pharmaceuticals Ltd (ASX:TLX) continues its upward trajectory, with shares climbing 1.5% in Friday morning trade to AU$28.22. This marks an impressive 112.6% gain over the past year, significantly boosting investor returns.